PFE : Phase 1/2 Results Show Bleeding Control In Highest Dose Cohort After Hemophilia A Gene Therapy
13/12 03:10
(RTTNews) - Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years following Hemophilia A gene therapy....